Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOV7J4
|
|||
| Drug Name |
Selgantolimod
|
|||
| Synonyms |
2004677-13-6; 4-yl)amino]-2-methylhexan-1-ol; GS-9688; (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-; (2R)-2-[(2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino]-2-methylhexan-1-ol; (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol; Selgantolimod (USAN/INN); CHEMBL4594258; SCHEMBL18109405; GTPL10889; EX-A4247; GS9688; HY-109137; compound (R)-7 [PMID: 32407112]; CS-0086927; D11871; U57
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis B [ICD-11: 1E51; ICD-10: B18.1] | Phase 2 | [1] | |
| Company |
Gilead Sciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H20FN5O
|
|||
| Canonical SMILES |
CCCCC(C)(CO)NC1=NC(=NC2=C1N=CC(=C2)F)N
|
|||
| InChI |
1S/C14H20FN5O/c1-3-4-5-14(2,8-21)20-12-11-10(18-13(16)19-12)6-9(15)7-17-11/h6-7,21H,3-5,8H2,1-2H3,(H3,16,18,19,20)/t14-/m1/s1
|
|||
| InChIKey |
HTCJUBZBSJQWBW-CQSZACIVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor 8 (TLR8) | Target Info | Agonist | [2] |
| KEGG Pathway | Toll-like receptor signaling pathway | |||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Panther Pathway | Toll receptor signaling pathway | |||
| Reactome | Trafficking and processing of endosomal TLR | |||
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | ||||
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Toll-Like Receptors Cascades | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| Trafficking and processing of endosomal TLR | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03491553) Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Adults With Chronic Hepatitis B. U.S. National Institutes of Health. | |||
| REF 2 | Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.